Publicaciones (33) Publicaciones de María Elena Díaz Rodríguez

2024

  1. Trastuzumab deruxtecan in breast cancer

    Critical Reviews in Oncology/Hematology, Vol. 198

2022

  1. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. Antitumoral properties of the nutritional supplement ocoxin oral solution: A comprehensive review

    Nutrients, Vol. 12, Núm. 9, pp. 1-18

2019

  1. Central role of cell cycle regulation in the antitumoral action of ocoxin

    Nutrients, Vol. 11, Núm. 5

  2. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells

    Cancer Letters, Vol. 453, pp. 34-44

2018

  1. Antitumoral effect of Ocoxin, a natural compound-containing nutritional supplement, in small cell lung cancer

    International Journal of Oncology, Vol. 53, Núm. 1, pp. 113-123

2017

  1. Antitumoral effect of ocoxin in hepatocellular carcinoma

    Oncology Letters, Vol. 14, Núm. 2, pp. 1950-1958

  2. Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity

    Cancer Research, Vol. 77, Núm. 17, pp. 4639-4651

  3. The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma

    Haematologica, Vol. 102, Núm. 12, pp. 2113-2124

2016

  1. Antitumoral effect of Ocoxin on acute myeloid leukemia

    Oncotarget, Vol. 7, Núm. 5, pp. 6231-6242

  2. Modulation of cereblon levels by anti-myeloma agents

    Leukemia and Lymphoma, Vol. 57, Núm. 1, pp. 168-176

2015

  1. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

    Leukemia, Vol. 29, Núm. 3, pp. 705-714

2014

  1. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 Inhibition as an antimyeloma strategy

    Molecular Cancer Therapeutics, Vol. 13, Núm. 2, pp. 504-516

  2. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: Implications in myeloma progression and myeloma bone disease

    Oncotarget, Vol. 5, Núm. 18, pp. 8284-8305

2012

  1. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

    Leukemia, Vol. 26, Núm. 8, pp. 1862-1869

2011

  1. A modular approach to trim cellular targets in anticancer drug discovery

    Bioorganic and Medicinal Chemistry Letters, Vol. 21, Núm. 22, pp. 6641-6645

  2. Deficient spindle assembly checkpoint in multiple myeloma

    PLoS ONE, Vol. 6, Núm. 11

2010

  1. Multisite phosphorylation of Erk5 in mitosis

    Journal of Cell Science, Vol. 123, Núm. 18, pp. 3146-3156

  2. Targeting the kinetochore in cancer therapy: The Ndc80/Hec1 complex

    Current Drug Therapy, Vol. 5, Núm. 1, pp. 29-35